CRISPR Therapeutics
CRSP
155 hedge funds and large institutions have $631M invested in CRISPR Therapeutics in 2018 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 52 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 44
1.64% less ownership
Funds ownership: 44.27% → 42.63% (-1.6%)
13% less funds holding
Funds holding: 179 → 155 (-24)
35% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $17.5M
37% less capital invested
Capital invested by funds: $1.01B → $631M (-$377M)
42% less first-time investments, than exits
New positions opened: 30 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
+$20.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$14.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.04M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.22M |
| 5 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$6.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$24M |
| 2 |
O
OrbiMed
New York
|
-$22M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$10.1M |
| 4 |
CC
Casdin Capital
New York
|
-$9.76M |
| 5 |
JP Morgan Chase
New York
|
-$9.34M |
CRSP Hedge Fund Activity: Q4 2018 in Review
155 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2018, worth a combined $631M — down 37% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of CRSP and 30 opened new positions — a net loss of 22 holders — while 44 trimmed existing stakes and 41 added.
The largest buyer was Ontario Teachers' Pension Plan Board, opening a new position worth an estimated $20.2M. The largest seller was Jennison Associates, exiting entirely with an estimated $24M sold.
- 155 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2018, down from 179 in Q3 2018.
- Funds reported $631M of CRISPR Therapeutics stock for Q4 2018, down 37% quarter-over-quarter.
- 30 funds opened new CRISPR Therapeutics positions in Q4 2018 and 52 closed out, a net change of -22 holders.
- The largest CRISPR Therapeutics buyer in Q4 2018 was Ontario Teachers' Pension Plan Board, an estimated $20.2M added.
- The largest CRISPR Therapeutics seller in Q4 2018 was Jennison Associates, an estimated $24M sold.
Based on aggregated 13F filings for Q4 2018.